Cargando…
New cell sources for CAR-based immunotherapy
Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved striking success in some hematological malignancies in preclinical and clinical trials, resulting in six FDA-approved CAR-T products currently availa...
Autores principales: | Mazinani, Marzieh, Rahbarizadeh, Fatemeh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163725/ https://www.ncbi.nlm.nih.gov/pubmed/37147740 http://dx.doi.org/10.1186/s40364-023-00482-9 |
Ejemplares similares
-
CAR-T cell potency: from structural elements to vector backbone components
por: Mazinani, Marzieh, et al.
Publicado: (2022) -
Novel antigens of CAR T cell therapy: New roads; old destination
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021) -
CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2021) -
Strategies for Dodging the Obstacles in CAR T Cell Therapy
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021) -
The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy
por: Arman, Inbar, et al.
Publicado: (2022)